Richard E. Clark
De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial
Clark, Richard E.; Polydoros, Fotios; Apperley, Jane F.; Milojkovic, Dragana; Pocock, Christopher; Smith, Graeme; Byrne, Jenny L.; de Lavallade, Hugues; O'Brien, Stephen G.; Coffey, Tony; Foroni, Letizia; Copland, Mhairi
Authors
Fotios Polydoros
Jane F. Apperley
Dragana Milojkovic
Christopher Pocock
Graeme Smith
Jenny L. Byrne
Hugues de Lavallade
Stephen G. O'Brien
Tony Coffey
Letizia Foroni
Mhairi Copland
Abstract
BACKGROUND: Discontinuation of tyrosine kinase inhibitor (TKI) therapy is feasible for some patients with chronic myeloid leukaemia (CML) with deep molecular responses, defined as stable MR4 (BCR-ABL1/ABL1 ratio 0.1%) on two consecutive samples. The study endpoint is the proportion of patients who lose their MMR on de-escalation and regain MMR on TKI resumption. The trial was registered at https://clinicaltrials.gov/ as NCT 01804985.
FINDINGS: During the 12 months of half-dose therapy, 12 patients had molecular recurrence, all of whom regained MMR within 4 months of full dose TKI resumption. Recurrence was lower in the MR4 cohort (3 of 121 evaluable patients; 2.5%, 90% CI: 0.2-4.8%) than in the MMR cohort (9 of 48 evaluable patients; 18.8%, 90% CI: 9.5-28%) (p = 0.0007), but was unrelated to prior TKI or TKI therapy duration. Many adverse events improved during the first 3 months of de-escalation, though not thereafter. Overall, de-escalation saved 46.7% from an expected TKI budget (without de-escalation) of £4,156,969.
INTERPRETATION: TKI de-escalation is safe for the vast majority of patients with excellent responses to TKI therapy, and is associated with improvement in symptoms and significant financial savings. The data imply that lower TKI doses may maintain responses in these patients.
Citation
Clark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Pocock, C., Smith, G., …Copland, M. (2017). De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematology, 4(7), e310-e316. https://doi.org/10.1016/S2352-3026%2817%2930066-2
Journal Article Type | Article |
---|---|
Acceptance Date | Apr 19, 2017 |
Online Publication Date | May 26, 2017 |
Publication Date | Jul 1, 2017 |
Deposit Date | Dec 14, 2017 |
Publicly Available Date | Mar 29, 2024 |
Journal | The Lancet Haematology |
Electronic ISSN | 2352-3026 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 4 |
Issue | 7 |
Pages | e310-e316 |
DOI | https://doi.org/10.1016/S2352-3026%2817%2930066-2 |
Keywords | chronic myeloid leukaemia, tyrosine kinase inhibitors, stopping treatment, imatinib, nilotinib, dasatinib |
Public URL | https://nottingham-repository.worktribe.com/output/869421 |
Publisher URL | https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30066-2/fulltext |
Files
paper174DESTINYpaperLancet Haematology FINAL.pdf
(1.1 Mb)
PDF
paper174 DESTINYpaperLancetHaematologySupplementary materials.pdf
(165 Kb)
PDF
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: digital-library-support@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search